The House Appropriations Committee directed the FDA to speed up IND sign-off timelines, arguing the agency should reform how it processes new clinical trial authorizations to keep pace with global competitors. The direction is part of a broader policy push in Washington focused on national competitiveness in drug development. Separately, industry stakeholders used FDA’s CNPV pilot listening session to press for clarity and transparency around how the ultra-accelerated review program will operate. The Commissioner’s National Priority Voucher initiative offers short review windows and sponsor-review communication mechanisms, but the FDA heard mixed feedback. Together, the items spotlight regulatory timelines and program design as near-term drivers of biotech planning—especially for sponsors weighing faster pathways against submission and operational uncertainty.